Literature DB >> 8499641

Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cells.

M H Freedman1, T Grunberger, P Correa, A A Axelrad, I D Dube, A Cohen.   

Abstract

Blast colony assays were performed on freshly obtained bone marrow samples from 19 newly diagnosed or relapsed children with acute lymphoblastic leukemia (ALL) of B lineage to determine the effect of added granulocyte-monocyte colony-stimulating factor (GM-CSF). Of the 19 marrow samples tested, 7 responded to GM-CSF with a mean increase in ALL blast colonies of 346%. Blast cells from one of the responders chosen for flow cytometric study showed expression of GM-CSF receptors on 38% of cells. These findings prompted us to establish five ALL cell lines of diverse phenotypes to examine the expression of GM-CSF and GM-CSF receptor genes in human leukemia, and to determine the role of GM-CSF in autocrine and paracrine growth control of ALL cells. One line, termed G2, manifested a GM-CSF-mediated autocrine pattern of cell growth with the following features: G2 blast colony growth in a serum-free system without added growth factor was density dependent; exogenous GM-CSF augmented G2 colony formation when the cells were seeded at low density; G2 cells constitutively expressed mRNA for GM-CSF and GM-CSF receptor; G2 cells also produced and secreted measurable amounts of GM-CSF into cell culture supernatant; and, monoclonal anti-GM-CSF antibodies abolished G2 colony growth when added to cultures with cells seeded at low density without growth factors. Of the other four ALL cell lines, three expressed mRNA for GM-CSF receptor and responded in vitro to added GM-CSF with increased blast colony growth; however, none of these four cell lines expressed mRNA for constitutive production of GM-CSF. A fifth ALL cell line lacked receptors for GM-CSF and did not respond in clonogenic assays to added GM-CSF. Thus, a bioregulator of normal hematopoiesis plays a central role in autocrine growth control of G2 ALL cells, and an important paracrine growth-promoting role in three of four other ALL cell lines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499641

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.

Authors:  Jung Kwon Lee; SungMyung Kang; Xidi Wang; Jesusa L Rosales; Xu Gao; Hee-Guk Byun; Yan Jin; Songbin Fu; Jinghua Wang; Ki-Young Lee
Journal:  Blood       Date:  2019-02-28       Impact factor: 22.113

2.  Atypical PKC-zeta regulates SDF-1-mediated migration and development of human CD34+ progenitor cells.

Authors:  Isabelle Petit; Polina Goichberg; Asaf Spiegel; Amnon Peled; Chaya Brodie; Rony Seger; Arnon Nagler; Ronen Alon; Tsvee Lapidot
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

3.  Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects.

Authors:  Kanji Uchida; Koh Nakata; Takuji Suzuki; Maurizio Luisetti; Masato Watanabe; Diana E Koch; Carrie A Stevens; David C Beck; Lee A Denson; Brenna C Carey; Naoto Keicho; Jeffrey P Krischer; Yoshitsugu Yamada; Bruce C Trapnell
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

4.  Specific human granulocyte-macrophage colony-stimulating factor antagonists.

Authors:  T R Hercus; C J Bagley; B Cambareri; M Dottore; J M Woodcock; M A Vadas; M F Shannon; A F Lopez
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

5.  Further activation of FLT3 mutants by FLT3 ligand.

Authors:  R Zheng; E Bailey; B Nguyen; X Yang; O Piloto; M Levis; D Small
Journal:  Oncogene       Date:  2011-04-25       Impact factor: 9.867

Review 6.  Testing electromagnetic fields for potential carcinogenic activity: a critical review of animal models.

Authors:  J McCann; R Kavet; C N Rafferty
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.